Oil prices rise from over 1-mth low with Russia crude buyer sanctions in focus
BOSTON - Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company with a market capitalization of $291 million, has announced the publication of results from its Phase 1a trial of navenibart, a potential therapy for hereditary angioedema (HAE). According to InvestingPro analysis, the company’s stock appears undervalued despite falling over 54% in the past six months. The study, published in the Annals of Allergy, Asthma & Immunology, indicates that the drug could be administered every three to six months, offering a long-acting treatment option for HAE.
The trial’s findings suggest that navenibart has a mean half-life of 82 to 105 days at doses of 300 mg or higher. Its inhibition of plasma kallikrein activity, a key factor in HAE attacks, was statistically significant compared to placebo. Moreover, the drug was well-tolerated with a similar rate of adverse events to placebo, and no serious adverse events were reported. The company maintains a strong financial position with a current ratio of 17.49, indicating ample liquidity to fund its clinical programs.
Christopher Morabito, M.D., Chief Medical Officer at Astria Therapeutics, expressed optimism about the drug’s potential as a first-choice therapy for HAE. The Phase 1a trial results have set the stage for the ongoing ALPHA-ORBIT Phase 3 trial, which aims to establish navenibart as a life-changing therapy for HAE patients globally.
Navenibart is an investigational monoclonal antibody inhibitor of plasma kallikrein. It is currently in Phase 3 development, with the goal of providing rapid and sustained prevention of HAE attacks. Astria Therapeutics is also developing another monoclonal antibody, STAR-0310, for the treatment of atopic dermatitis.
The company cautions that this press release contains forward-looking statements, which are not guarantees of future performance. These statements reflect current beliefs and expectations regarding the future of the business and are subject to risks and uncertainties that could cause actual results to differ materially. InvestingPro data reveals strong analyst optimism, with price targets ranging from $16 to $47, significantly above current trading levels. Discover more valuable insights and 7 additional ProTips with an InvestingPro subscription.
Astria Therapeutics’ mission is to develop therapies for patients and families affected by allergic and immunologic diseases, striving to become a leading company in the field. Information in this article is based on a press release statement.
In other recent news, Astria Therapeutics has received confirmation from Citizens JMP analysts of a Market Outperform rating with a $26.00 price target, reflecting confidence in the company’s ongoing clinical trials. The company is progressing with its Phase 3 ALPHA-ORBIT trial for navenibart, a treatment for Hereditary Angioedema (HAE), with results expected in early 2027. Extended follow-up data from the Phase 1b/2 trial of navenibart is anticipated around mid-2025, which is crucial for assessing the long-term efficacy of the treatment’s dosing intervals. Additionally, Astria Therapeutics plans to release initial clinical data for STAR-0310, an OX40 antagonist, in the third quarter of 2025. Meanwhile, JMP Securities has reiterated its Market Outperform rating for Astria Therapeutics, maintaining a $26.00 price target. The company is set to present data from its ongoing clinical trials at an upcoming conference, highlighting navenibart’s potential to sustainably reduce HAE attacks. These developments underscore Astria Therapeutics’ strategic progress in its product pipeline and potential growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.